Baillie Gifford & Co
STRO icon

Baillie Gifford & Co’s Sutro Biopharma STRO Stock Holding History

Baillie Gifford & Co’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-4,879
Closed -$89.8K – 282
2024
Q4 		$89.8K Sell
4,879
-147,055
-97% -$4.49M ﹤0.01% 258
2024
Q3 		$5.26M Sell
151,934
-32,941
-18% -$1.29M ﹤0.01% 230
2024
Q2 		$5.42M Buy
184,875
+184
+0.1% +$7.28K ﹤0.01% 234
2024
Q1 		$10.4M Sell
184,691
-1,994
-1% -$88.1K 0.01% 224
2023
Q4 		$8.01M Sell
186,685
-80
-0% -$2.54K 0.01% 230
2023
Q3 		$6.48M Hold
186,765
– – 0.01% 229
2023
Q2 		$8.68M Hold
186,765
– – 0.01% 224
2023
Q1 		$8.63M Sell
186,765
-97
-0.1% -$6.16K 0.01% 225
2022
Q4 		$15.1M Hold
186,862
– – 0.02% 198
2022
Q3 		$10.4M Buy
186,862
+344
+0.2% +$20.4K 0.01% 214
2022
Q2 		$9.72M Sell
186,518
-332
-0.2% -$18.5K 0.01% 216
2022
Q1 		$15.4M Buy
186,850
+1,325
+0.7% +$126K 0.01% 216
2021
Q4 		$27.6M Buy
185,525
+6,031
+3% +$1.08M 0.02% 208
2021
Q3 		$33.9M Buy
179,494
+77
+0% +$14.6K 0.02% 204
2021
Q2 		$33.4M Buy
179,417
+9,852
+6% +$1.93M 0.02% 209
2021
Q1 		$38.6M Hold
169,565
– – 0.02% 198
2020
Q4 		$36.8M Hold
169,565
– – 0.02% 177
2020
Q3 		$17M Buy
169,565
+19,565
+13% +$1.85M 0.01% 190
2020
Q2 		$11.6M Buy
+150,000
New +$14.4M 0.01% 189

Other funds holding STRO

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Baillie Gifford & Co's STRO Position: Q1 2025 in Review

Baillie Gifford & Co sold out of Sutro Biopharma (STRO) in Q1 2025, closing a stake of 4,879 shares — an estimated $89.8K sold.

Baillie Gifford & Co first reported a position in STRO in Q2 2020 and held it in 19 quarters. The position peaked at $38.6M in Q1 2021. 112 funds tracked by Wall St. Rank hold STRO as of Q1 2025.

  • Baillie Gifford & Co reported no remaining Sutro Biopharma position as of Q1 2025 after selling out during the quarter.
  • Baillie Gifford & Co sold 4,879 Sutro Biopharma shares in Q1 2025, an estimated $89.8K.
  • Baillie Gifford & Co first reported a position in Sutro Biopharma in Q2 2020 and held it in 19 quarters.
  • Baillie Gifford & Co's Sutro Biopharma position peaked at $38.6M in Q1 2021.
  • 112 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2025.

Based on Baillie Gifford & Co's 13F filing for Q1 2025, filed 7 May 2025.